Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Operating Expenses (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Operating Expenses for 16 consecutive years, with $22.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses rose 3.56% to $22.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $93.6 million, a 48.97% decrease, with the full-year FY2024 number at $89.6 million, down 50.41% from a year prior.
  • Operating Expenses was $22.0 million for Q3 2025 at Gyre Therapeutics, down from $25.5 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $124.0 million in Q4 2022 to a low of -$51.5 million in Q2 2022.
  • A 5-year average of $27.6 million and a median of $22.0 million in 2025 define the central range for Operating Expenses.
  • Biggest YoY gain for Operating Expenses was 444.79% in 2022; the steepest drop was 344.84% in 2022.
  • Gyre Therapeutics' Operating Expenses stood at $22.8 million in 2021, then skyrocketed by 444.79% to $124.0 million in 2022, then fell by 2.35% to $121.0 million in 2023, then tumbled by 77.52% to $27.2 million in 2024, then fell by 19.1% to $22.0 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Operating Expenses are $22.0 million (Q3 2025), $25.5 million (Q2 2025), and $18.9 million (Q1 2025).